Cite
Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study.
MLA
Kudrimoti, Mahesh, et al. “Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study.” Journal of Biotechnology, vol. 239, Dec. 2016, pp. 115–25. EBSCOhost, https://doi.org/10.1016/j.jbiotec.2016.10.010.
APA
Kudrimoti, M., Curtis, A., Azawi, S., Worden, F., Katz, S., Adkins, D., Bonomi, M., Elder, J., Sonis, S. T., Straube, R., & Donini, O. (2016). Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. Journal of Biotechnology, 239, 115–125. https://doi.org/10.1016/j.jbiotec.2016.10.010
Chicago
Kudrimoti, Mahesh, Amarintha Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, et al. 2016. “Dusquetide: A Novel Innate Defense Regulator Demonstrating a Significant and Consistent Reduction in the Duration of Oral Mucositis in Preclinical Data and a Randomized, Placebo-Controlled Phase 2a Clinical Study.” Journal of Biotechnology 239 (December): 115–25. doi:10.1016/j.jbiotec.2016.10.010.